Study Evaluates Optimal Second-Line ART Regimens For HIV

Infectious Disease Advisor (6/27, Nye) reports, “Dolutegravir (DTG) plus ritonavir-boosted darunavir (DRV/r) and DTG with tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC) or emtricitabine (FTC) are both noninferior to DRV/r plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) for HIV virologic suppression in patients who experience treatment failure on non-NRTI (NNRTI)-based first-line antiretroviral therapy (ART), according to study results published in The Lancet HIV.” In the study, “at week 48, virologic suppression was observed among 75% of patients in the standard care group, 84% of those in the DRV/r plus DTG group, and 78% of those in the DTG/TDF plus 3TC or FTC group.”